Emerging Stocks Down Under 9 March 2021: PYC Therapeutics, Sprint Technology Solutions, Yojee

PYC Therapeutics: Helping us all see better

In today’s edition of Emerging Stocks Down Under, formerly known as Phylogica, PYC Therapeutics is finally making headway with its delivery of RNA-based therapy in the treatment of ocular diseases. Since the company’s first drug-delivery campaign in early 2020, PYC’s share price has leapt to a high of 19 cents late in the year, from its previous low of 5 cents in the nightmare month of March 2020. As the company builds momentum towards human trials, there is already much investor excitement about the potential application of its cell-penetrating peptide technology in specific eye diseases.

Also in today’s edition, a look at IT and telecommunications provider Sprint Technology Solutions (ASX: ST1) and logistics supply chain platform developer Yojee (ASX: YOJ).

 

 

Click here to read the previous edition of Emerging Stocks Down Under published 2 March 2021

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.